These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 30511426)

  • 1. Aerobic exercise reduces triglycerides by targeting apolipoprotein C3 in patients with coronary heart disease.
    Wang Y; Shen L; Xu D
    Clin Cardiol; 2019 Jan; 42(1):56-61. PubMed ID: 30511426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Sst I polymorphism in apolipoprotein C3 gene with hypertriglyceridaemia in coronary atherosclerotic heart disease and type II diabetes mellitus in Chinese population.
    Liu HK; Li XF; Zhang SZ; Ren Y; Yong-Xin ; Liu YQ; Wang CT; Chen X; Hu YM; Zhang L
    Yi Chuan Xue Bao; 2005 Jan; 32(1):11-8. PubMed ID: 15715433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein A5 and apolipoprotein C3 single nucleotide polymorphisms are correlated with an increased risk of coronary heart disease: a case-control and meta-analysis study.
    Yang G; Lei MM; Yu CL; Liu XX; An Z; Song CL
    Lipids Health Dis; 2015 Sep; 14():113. PubMed ID: 26387083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.
    Gaudet D; Alexander VJ; Baker BF; Brisson D; Tremblay K; Singleton W; Geary RS; Hughes SG; Viney NJ; Graham MJ; Crooke RM; Witztum JL; Brunzell JD; Kastelein JJ
    N Engl J Med; 2015 Jul; 373(5):438-47. PubMed ID: 26222559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss-of-function mutations in APOC3, triglycerides, and coronary disease.
    ; Crosby J; Peloso GM; Auer PL; Crosslin DR; Stitziel NO; Lange LA; Lu Y; Tang ZZ; Zhang H; Hindy G; Masca N; Stirrups K; Kanoni S; Do R; Jun G; Hu Y; Kang HM; Xue C; Goel A; Farrall M; Duga S; Merlini PA; Asselta R; Girelli D; Olivieri O; Martinelli N; Yin W; Reilly D; Speliotes E; Fox CS; Hveem K; Holmen OL; Nikpay M; Farlow DN; Assimes TL; Franceschini N; Robinson J; North KE; Martin LW; DePristo M; Gupta N; Escher SA; Jansson JH; Van Zuydam N; Palmer CN; Wareham N; Koch W; Meitinger T; Peters A; Lieb W; Erbel R; Konig IR; Kruppa J; Degenhardt F; Gottesman O; Bottinger EP; O'Donnell CJ; Psaty BM; Ballantyne CM; Abecasis G; Ordovas JM; Melander O; Watkins H; Orho-Melander M; Ardissino D; Loos RJ; McPherson R; Willer CJ; Erdmann J; Hall AS; Samani NJ; Deloukas P; Schunkert H; Wilson JG; Kooperberg C; Rich SS; Tracy RP; Lin DY; Altshuler D; Gabriel S; Nickerson DA; Jarvik GP; Cupples LA; Reiner AP; Boerwinkle E; Kathiresan S
    N Engl J Med; 2014 Jul; 371(1):22-31. PubMed ID: 24941081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An APOC3 3'UTR variant associated with plasma triglycerides levels and coronary heart disease by creating a functional miR-4271 binding site.
    Hu SL; Cui GL; Huang J; Jiang JG; Wang DW
    Sci Rep; 2016 Sep; 6():32700. PubMed ID: 27624799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The -1131 T>C and S19W APOA5 gene polymorphisms are associated with high levels of triglycerides and apolipoprotein C-III, but not with coronary artery disease: an angiographic study.
    Martinelli N; Trabetti E; Bassi A; Girelli D; Friso S; Pizzolo F; Sandri M; Malerba G; Pignatti PF; Corrocher R; Olivieri O
    Atherosclerosis; 2007 Apr; 191(2):409-17. PubMed ID: 16682041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Common APOC3 variants are associated with circulating ApoC-III and VLDL cholesterol but not with total apolipoprotein B and coronary artery disease.
    Silbernagel G; Scharnagl H; Kleber ME; Hoffmann MM; Delgado G; Stojakovic T; Gary T; Zeng L; Ritsch A; Zewinger S; Speer T; Schunkert H; Landmesser U; März W; Grammer TB
    Atherosclerosis; 2020 Oct; 311():84-90. PubMed ID: 32949947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia.
    Gaudet D; Clifton P; Sullivan D; Baker J; Schwabe C; Thackwray S; Scott R; Hamilton J; Given B; Melquist S; Zhou R; Chang T; San Martin J; Watts GF; Goldberg IJ; Knowles JW; Hegele RA; Ballantyne CM
    NEJM Evid; 2023 Dec; 2(12):EVIDoa2200325. PubMed ID: 38320498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of cardiac rehabilitation and exercise training on low-density lipoprotein cholesterol in patients with hypertriglyceridemia and coronary artery disease.
    Lavie CJ; Milani RV
    Am J Cardiol; 1994 Dec; 74(12):1192-5. PubMed ID: 7977088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA-based therapies targeting APOC3 lower triglyceride levels in patients with hypertriglyceridaemia.
    Huynh K
    Nat Rev Cardiol; 2024 Jun; 21(6):353. PubMed ID: 38654089
    [No Abstract]   [Full Text] [Related]  

  • 12. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease.
    Jørgensen AB; Frikke-Schmidt R; Nordestgaard BG; Tybjærg-Hansen A
    N Engl J Med; 2014 Jul; 371(1):32-41. PubMed ID: 24941082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders.
    Onat A; Hergenç G; Sansoy V; Fobker M; Ceyhan K; Toprak S; Assmann G
    Atherosclerosis; 2003 May; 168(1):81-9. PubMed ID: 12732390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein C3 genetic polymorphisms are associated with lipids and coronary artery disease in a Chinese population.
    Cui F; Li K; Li Y; Zhang X; An C
    Lipids Health Dis; 2014 Nov; 13():170. PubMed ID: 25380998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic characterisation of disturbances in the APOC3/triglyceride-rich lipoprotein pathway through sample-based recall by genotype.
    Corbin LJ; Hughes DA; Chetwynd AJ; Taylor AE; Southam AD; Jankevics A; Weber RJM; Groom A; Dunn WB; Timpson NJ
    Metabolomics; 2020 Jun; 16(6):69. PubMed ID: 32494907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum triglyceride, high-density lipoprotein cholesterol, apolipoprotein B, and coronary heart disease in a Chinese population undergoing coronary angiography.
    Ling Y; Jiang J; Wu B; Gao X
    J Clin Lipidol; 2017; 11(3):646-656. PubMed ID: 28506386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice.
    Cheng X; Yamauchi J; Lee S; Zhang T; Gong Z; Muzumdar R; Qu S; Dong HH
    J Biol Chem; 2017 Mar; 292(9):3692-3705. PubMed ID: 28115523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coronary Heart Disease Risk Associated with Primary Isolated Hypertriglyceridemia; a Population-Based Study.
    Saadatagah S; Pasha AK; Alhalabi L; Sandhyavenu H; Farwati M; Smith CY; Wood-Wentz CM; Bailey KR; Kullo IJ
    J Am Heart Assoc; 2021 Jun; 10(11):e019343. PubMed ID: 34032140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma apolipoprotein A5 and triglycerides in type 2 diabetes.
    Dallinga-Thie GM; van Tol A; Hattori H; van Vark-van der Zee LC; Jansen H; Sijbrands EJ;
    Diabetologia; 2006 Jul; 49(7):1505-11. PubMed ID: 16752169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertriglyceridemia and coronaryheart disease risk.
    Rosenson RS
    Cardiol Rev; 1999; 7(6):342-8. PubMed ID: 11208246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.